67268-37-5

Usage

Biochem/physiol Actions

SUN is am orally active and potent DAAO (DAO) inhibitor, which increases D-serine cerebellar and plasma concentrations. SUN was effective in rat models of neuropathic and inflammatory pain.

InChI:InChI=1/C9H9NO3/c1-2-12-9(11)7-5-8-6(10-7)3-4-13-8/h3-5,10H,2H2,1H3

Upstream product

• 164667-41-8 methyl 2-azido-2-(furan-2-yl)acrylate 
• 98-01-1 furfural 
• 1207616-81-6 2-(2-morpholinoacetoxy)ethyl 4H-furo[3,2-b]pyrrole-5-carboxylate 
• 1207616-80-5 1-acetoxy-2-methylpropyl 4H-furo[3,2-b]pyrrole-5-carboxylate 
• 1207616-79-2 1-(cyclohexyloxycarbonyloxy)ethyl 4H-furo[3,2-b]pyrrole-5-carboxylate 
• 1207616-78-1 acetoxymethyl 4H-furo[3,2-b]pyrrole-5-carboxylate 
• 1207616-77-0 1-(tert-butoxycarbonyloxy)ethyl 4H-furo[3,2-b]pyrrole-5-carboxylate 
• 1207616-76-9 1-(isopropoxycarbonyloxy)ethyl 4H-furo[3,2-b]pyrrole-5-carboxylate 
• 1207616-75-8 1-(isobutyryloxy)ethyl 4H-furo[3,2-b]pyrrole-5-carboxylate 
• 1207616-74-7 1-(propionyloxy)ethyl 4H-furo[3,2-b]pyrrole-5-carboxylate 
• 1207616-73-6 1-acetoxyethyl 4H-furo[3,2-b]pyrrole-5-carboxylate 
• 1207616-72-5 2-morpholinoethyl 4h-furo[3,2-b]pyrrole-5-carboxylate 
• 1207616-71-4 (1H-imidazol-1-yl)methyl 4H-furo[3,2-b]pyrrole-5-carboxylate 
• 1207616-70-3 2-(1H-imidazol-1-yl)ethyl 4h-furo[3,2-b]pyrrole-5-carboxylate 

Downstream Products

• 250-91-9 furo<3,2-b>pyrrole 
• 1263388-08-4 2-methoxyphenyl 4H-furo[3,2-b]pyrrole-5-carboxylate 

Relevant academic research and scientific papers

D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF

The present invention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N—H, O, S, or absent is a single bond or a double bond; each of X, Y, and Z, independentl

PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE

The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D-amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective.

PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE

The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D- amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective.

The discovery of fused pyrrole carboxylic acids as novel, potent d-amino acid oxidase (DAO) inhibitors

The 'NMDA hypofunction hypothesis of schizophrenia' can be tested in a number of ways. DAO is the enzyme primarily responsible for the metabolism of d-serine, a co-agonist for the NMDA receptor. We identified novel DAO inhibitors, in particular, acid 1, which demonstrated moderate potency for DAO in vitro and ex vivo, and raised plasma d-serine levels after dosing ip to rats. In parallel, analogues were prepared to survey the SARs of 1.

FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE

This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O?X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.

USE OF FUSED PYRROLE CARBOXYLIC ACIDS FOR THE TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES AS D-AMINO ACID OXIDASE INHIBITORS

The present invention provides the use of fused pyrrole carboxylic acids of formula (I) for the manufacture of a medicament to inhibit D-amino acid oxidase, particularly for the treatment of neurodegenerative and psychiatric disorders or diseases; certain

SYNTHESIS AND REACTIONS OF SUBSTITUTED FUROPYRROLE DERIVATIVES

Preparation of ethyl 2-methylfuropyrrole-5-carboxylate and 2-bromofuropyrrole-5-carboxylate, as well as alkylation and hydrolysis of ethyl 2-methylfuropyrrole-5-carboxylate, ethyl furopyrrole-5-carboxylate and ethyl (3,4-dichlo